^
Association details:
| Biomarker: | EGFR exon 20 insertion + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Afatinib treatment in a large real-world cohort of non-small cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
Published date:
09/24/2021
Excerpt:
Exon 20 insertion and dT790MHAF patients demonstrated a significantly shortened PFS (2.6 and 4.1 months) compared to EGFR common mutation, dT790MLAF and other uncommon mutation patients (15.1, 27.0 and 18.4 months; p= 3x10-8 )….Afatinib-treated NSCLC patients presented an EGFR genotype-specific pattern of disease progression and outcome.
DOI:
10.1002/ijc.33821
